升血小板胶囊对肿瘤化疗相关性血小板减少症的疗效分析  

Analysis of therapeutic effect of Sheng Xuexiaoban capsules on chemotherapy-related thrombocytopenia

作　　者：赵娟芝 刘春华[2] 李景 梁嘉碧[1] 朱风雷 罗文基[1] ZHAO Juanzhi;LIU Chunhua;LI Jing;LIANG Jiabi;ZHU Fenglei;LUO Wenji(Department of Pharmacy,the Fifth Affiliated Hospital Sun Yat-sen University,Zhuhai 519000,Guangdong Province,China;Department of Infectious Diseases,Liaocheng People's Hospital,Liaocheng 252000,Shandong Province,China;Jiangsu Famous Medicine Technology Co.,Ltd.Nanjing 210003,Jiangsu Province,China)

机构地区：[1]中山大学附属第五医院药学部,广东珠海519000 [2]聊城市人民医院感染科,山东聊城252000 [3]江苏法迈生医学科技有限公司,江苏南京210003

出　　处：《世界临床药物》2024年第5期490-496,共7页World Clinical Drug

摘　　要：目的探讨真实世界中升血小板胶囊用于治疗肿瘤化疗相关性血小板减少症(chemotherapy-induced thrombocytopenia,CIT)的人群特征及临床疗效,在广泛人群中使用的有效性、安全性,临床上联合用药合理性及不同联合用药间疗效差异。方法采用回顾性研究,选取医院2812例使用升血小板胶囊的肿瘤CIT患者信息,根据联合用药分4组,A治疗组1522例(单用升血小板胶囊),B治疗组719例(联合重组人血小板生成素注射液),C治疗组786例(联合白介素11)以及D治疗组9例(联合海曲泊帕乙醇胺片)。比较治疗前后血小板计数的变化情况、CIT分级。结果与治疗前比较,A、B、C治疗组患者治疗结束后血小板计数均上升,差异具有统计学意义(P<0.001);不同治疗分期中,四组的CIT分级之间的差异均有统计学意义(P<0.05)。结论升血小板胶囊能显著改善肿瘤CIT血小板水平,尤其联合重组人血小板生成素注射液、白介素-11效果明显,总体安全性较好,值得临床推广应用。Objective To investigate the population characteristics and clinical efficacy of Sheng Xuexiaoban capsules in the treatment of tumor chemotherapy-related thrombocytopenia(CIT)in the real word,and to observe its effectiveness and safety in a wide range of people,the rationality of clinical combination of drugs and the difference in efficacy of different combinations of drugs.Methods A retrospective study was conducted to select 2812 CIT patients treated with Sheng Xuexiaoban capsules,and they were divided into four groups according to the combination of drugs,1522 patients in treatment group A(Sheng Xuexiaoban capsules alone),719 patients in treatment group B(combined with recombinant human thrombopoietin injection),786 patients in treatment group C(combined with interleukin-11),and 9 patients in treatment group D(combined with hexapopethanolamine tablets).The changes of platelet count and CIT grade before and after the treatment were compared.Results Compared with before treatment,platelet counts in treatment groups A,B and C all increased after treatment,and the difference was statistically significant(P<0.001).In different treatment stages,the difference of CIT grading among the four groups was statistically significant(P<0.05).Conclusion Sheng Xuexiaoban capsules can significantly improve the platelet level of tumor chemotherapy-related thrombocytopenia,especially in combination with recombinant human thrombopoietin injection and interleukin-11,the overall safety is good,worthy of clinical promotion and application.

关 键 词：升血小板胶囊 化疗相关性血小板减少症 真实世界研究 临床疗效 联合用药 

分 类 号：R558.2[医药卫生—血液循环系统疾病]